Beware of the swinging pendulum: Anti-tumor necrosis factor monotherapy vs combination therapy for inflammatory bowel disease

Gastroenterology

Volumn 146, Issue 4, 2014, Pages 884-887

  Bressler, Brian ^a   Siegel, Corey A ^b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; IMMUNOMODULATING AGENT; METHOTREXATE; TUMOR NECROSIS FACTOR INHIBITOR;

COST EFFECTIVENESS ANALYSIS; HUMAN; IMMUNOMODULATION; IMMUNOSURVEILLANCE; INFLAMMATORY BOWEL DISEASE; MONOTHERAPY; PRIORITY JOURNAL; REVIEW;

ANTIBODIES, MONOCLONAL, HUMANIZED; CROHN DISEASE; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; IMMUNOLOGIC FACTORS; MALE; NEOPLASMS;

EID: 84896485463     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2014.02.018     Document Type: Editorial

References (23)

1. G.R. Lichtenstein, R.H. Diamond, and C.L. Wagner et al. Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials Aliment Pharmacol Ther 30 2009 210 226
2. J.R. Rosh, T. Gross, and P. Mamula et al. Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn's disease: a cautionary tale? Inflamm Bowel Dis 13 2007 1024 1030
3. J.F. Colombel, W.J. Sandborn, and W. Reinisch et al. Infliximab, azathioprine, or combination therapy for Crohn's disease N Engl J Med 362 2010 1383 1395
4. R. Panaccione, S. Ghosh, and S. Middleton et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis Gastroenterology 2013 Oct 25 [Epub ahead of print]
5. G. Van Assche, C. Magdelaine-Beuzelin, and G. D'Haens et al. Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial Gastroenterology 134 2008 1861 1868
6. M.T. Osterman, W.J. Sandborn, and J.F. Colombel et al. Increased risk of malignancy with adalimumab combination therapy, compared with monotherapy, for Crohn's disease Gastroenterology 146 2014 941 949
7. L. Peyrin-Biroulet, P. Deltenre, and N. de Suray et al. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials Clin Gastroenterol Hepatol 6 2008 644 653
8. G.R. Lichtenstein, B.G. Feagan, and R.D. Cohen et al. Drug therapies and the risk of malignancy in Crohn's disease: Results from the TREAT registry Am J Gastroenterol 109 2014 212 223
9. R.G. Armstrong, J. West, and T.R. Card Risk of cancer in inflammatory bowel disease treated with azathioprine: a UK population-based case-control study Am J Gastroenterol 105 2010 1604 1609
10. L.J. Herrinton, L. Liu, and X. Weng et al. Role of thiopurine and anti-TNF therapy in lymphoma in inflammatory bowel disease Am J Gastroenterol 106 2011 2146 2153
11. L. Beaugerie, N. Brousse, and A.M. Bouvier et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study Lancet 374 2009 1617 1625
12. C. Confavreux, P. Saddier, and J. Grimaud et al. Risk of cancer from azathioprine therapy in multiple sclerosis: a case-control study Neurology 46 1996 1607 1612
13. D.S. Kotlyar, M.T. Osterman, and R.H. Diamond et al. A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease Clin Gastroenterol Hepatol 9 2011 36 41.e1
14. A. Gutierrez-Dalmau, and J.M. Campistol Immunosuppressive therapy and malignancy in organ transplant recipients: a systematic review Drugs 67 2007 1167 1198
15. L. Peyrin-Biroulet, K. Khosrotehrani, and F. Carrat et al. Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease Gastroenterology 141 2011 1621 1628 e1-e5
16. M. Camus, P. Seksik, and A. Bourrier et al. Long-term outcome of patients with Crohn's disease who respond to azathioprine Clin Gastroenterol Hepatol 11 2013 389 394
17. B. Pasternak, H. Svanstrom, and K. Schmiegelow et al. Use of azathioprine and the risk of cancer in inflammatory bowel disease Am J Epidemiol 177 2013 1296 1305
18. C.A. Siegel, S.R. Finlayson, and B.E. Sands et al. Adverse events do not outweigh benefits of combination therapy for Crohn's disease in a decision analytic model Clin Gastroenterol Hepatol 10 2012 46 51
19. F.R. Johnson, S. Ozdemir, and C. Mansfield et al. Crohn's disease patients' risk-benefit preferences: serious adverse event risks versus treatment efficacy Gastroenterology 133 2007 769 779
20. F.R. Johnson, B. Hauber, and S. Ozdemir et al. Are gastroenterologists less tolerant of treatment risks than patients? Benefit-risk preferences in Crohn's disease management J Managed Care Pharm 16 2010 616 628
21. S. Saito, U. Shimizu, and Z. Nan et al. Economic impact of combination therapy with infliximab plus azathioprine for drug-refractory Crohn's disease: a cost-effectiveness analysis J Crohns Colitis 7 2013 167 174
22. G.Y. Melmed, B.M. Spiegel, and B. Bressler et al. The appropriateness of concomitant immunomodulators with anti-tumor necrosis factor agents for Crohn's disease: one size does not fit all Clin Gastroenterol Hepatol 8 2010 655 659
23. D.H. Solomon, J.M. Kremer, and M. Fisher et al. Comparative cancer risk associated with methotrexate, other non-biologic and biologic disease-modifying anti-rheumatic drugs Semin Arthritis Rheum 43 2014 489 497